News | February 20, 2022
GSK pauses phase III RSV maternal vaccine candidate programme
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Darolutamide is developed jointly by Bayer and Orion Corporation
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Urban, semi-urban and remote corners of the country will be catered using drone delivery technology
Glenmark received manufacturing and marketing approval from DCGI for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval process
Subscribe To Our Newsletter & Stay Updated
